Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herombopag with Immunosuppressants for Aplastic Anemia
NCT06009965Phase 4Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of hetrombopag in aplastic anemia (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Overall Response Rate at 24 weeks and 24-month Recurrence Rate. Status: unknown.
02
Drugs
hetrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06009965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06009965.